Tamoxifen: Five Versus Ten Years--Is the End in Sight?

This publication has 16 references indexed in Scilit:

• Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
  JNCI Journal of the National Cancer Institute, 2001
• Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit
  Controlled Clinical Trials, 1998
• Tamoxifen for early breast cancer: an overview of the randomised trials
  The Lancet, 1998
• Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
  JNCI Journal of the National Cancer Institute, 1996
• Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
  British Journal of Cancer, 1996
• Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *
  JNCI Journal of the National Cancer Institute, 1994
• Tamoxifen: Trials, Tribulations, and Trade-offs
  JNCI Journal of the National Cancer Institute, 1994
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
  The Lancet, 1992
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989
• Adjuvant Chemotherapy for Breast Cancer
  Published by American Medical Association (AMA) ,1985